Literature DB >> 32432816

Mortality in adults with chronic hepatitis B infection in the United States: a population-based study.

Kali Zhou1,2, Jennifer L Dodge1, Joshua Grab2, Eduard Poltavskiy2,3, Norah A Terrault1.   

Abstract

BACKGROUND: Chronic hepatitis B infection is an important contributor to mortality in the United States, yet impact of available and effective oral antivirals on mortality among infected individuals is unknown. AIMS: To compare risks and predictors of mortality in a recent time period between those with chronic, prior and no hepatitis B infection.
METHODS: This is a population-based cohort study of National Health and Nutrition Examination Surveys participants between 1999 and 2014 linked to National Death Index data. Adults aged 20 years or older with hepatitis B serologic testing were included. Outcomes of all-cause and liver-related mortality were evaluated using Cox regression.
RESULTS: Of 39 206 participants, 192 (0.5%) had chronic and 2694 (6.9%) had prior hepatitis B infection. The all-cause age/sex-standardised mortality rates for chronic, prior and uninfected were 21.4, 15.1 and 11.8 per 1000 person-years respectively. Liver-related mortality occurred at respective rates of 4.1, 0.3 and 0.1 per 1000 person-years. In multivariable analyses, those with chronic infection had 1.9-fold (95% CI 1.1-3.3) increased hazard of all-cause mortality and 13.3-fold (95% CI 3.9-45.5) increased hazard of liver-related mortality compared to uninfected. Predictors of all-cause mortality among chronic infection included heavy alcohol use (HR 18.3, 95% CI 3.3-100.6) and higher alanine aminotransferase (HR 1.02, 95% CI 1.00-1.03).
CONCLUSIONS: Mortality among adults living with chronic hepatitis B infection still exceeds that of uninfected despite availability of improved therapeutics. Identification of chronic infection, initiation of treatment among eligible and modulation of co-factors for disease progression are needed to improve survival.
© 2020 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32432816      PMCID: PMC7935406          DOI: 10.1111/apt.15803

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  28 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

3.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

Authors:  Joseph F Perz; Gregory L Armstrong; Leigh A Farrington; Yvan J F Hutin; Beth P Bell
Journal:  J Hepatol       Date:  2006-06-23       Impact factor: 25.083

4.  Provider, Patient, and Practice Factors Shape Hepatitis B Prevention and Management by Primary Care Providers.

Authors:  Nizar A Mukhtar; Priya Kathpalia; Joan F Hilton; Gene Lau; Albert Yu; Kevin Grumbach; Tung T Nguyen; Daniel Chan; Mandana Khalili
Journal:  J Clin Gastroenterol       Date:  2017-08       Impact factor: 3.062

5.  Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral Practices.

Authors:  Vy H Nguyen; An K Le; Huy N Trinh; Mimi Chung; Tiffani Johnson; Christopher Wong; Clifford Wong; Jian Zhang; Jiayi Li; Brian S Levitt; Huy A Nguyen; Khanh K Nguyen; Linda Henry; Ramsey Cheung; Mindie H Nguyen
Journal:  Clin Gastroenterol Hepatol       Date:  2018-10-13       Impact factor: 11.382

6.  Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up.

Authors:  Josepa Ribes; Ramon Clèries; Antoni Rubió; Josep Manel Hernández; Roberto Mazzara; Pedro Madoz; Teresa Casanovas; Aurora Casanova; Manel Gallen; Carmen Rodríguez; Victor Moreno; F Xavier Bosch
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

7.  Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.

Authors:  Donghee Kim; Andrew A Li; Chiranjeevi Gadiparthi; Muhammad Ali Khan; George Cholankeril; Jeffrey S Glenn; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2018-09-01       Impact factor: 22.682

8.  Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.

Authors:  Donghee Kim; Andrew A Li; Brandon J Perumpail; Chiranjeevi Gadiparthi; Won Kim; George Cholankeril; Jeffrey S Glenn; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Hepatology       Date:  2019-02-11       Impact factor: 17.425

9.  Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study.

Authors:  Elliot B Tapper; Neehar D Parikh
Journal:  BMJ       Date:  2018-07-18

10.  Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015.

Authors:  Anne Liu; An Le; Jian Zhang; Chris Wong; Clifford Wong; Linda Henry; Mindie H Nguyen
Journal:  Clin Transl Gastroenterol       Date:  2018-03-14       Impact factor: 4.488

View more
  1 in total

1.  Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis.

Authors:  Chi Zhang; Jia-Wen Li; Zhao Wu; Hong Zhao; Gui-Qiang Wang
Journal:  J Clin Transl Hepatol       Date:  2021-05-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.